GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide

Journal of Endocrinological Investigation

Volumn 24, Issue 4, 2001, Pages 209-216

  Attanasio, R ^a   Barausse, M ^a   Cozzi, Renato ^a,b  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b NONE   (Italy)

Author keywords

Acromegaly; GH; IGF I; Lanreotide; Somatostatin analogs; Tumor shrinkage

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; HEMOGLOBIN A1C; SOMATOMEDIN BINDING PROTEIN 1;

ACROMEGALY; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; DRUG EFFICACY; FEMALE; GALLSTONE; GASTROINTESTINAL SYMPTOM; GROWTH HORMONE BLOOD LEVEL; HEADACHE; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROSURGERY; RETROSPECTIVE STUDY; SLOW RELEASE FORMULATION; THERAPY RESISTANCE; TIME; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 0035030393     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03343849     Document Type: Article

References (26)

1. Wright A.D., Hill D.M., Lowy C., Fraser T.R. Mortality in acromegaly. Q. J. Med. 1970, 39: 1-16.
2. Bates A.S., Van't Hoff W., Jones J.M., Clayton R.N. An audit of outcome of treatment in acromegaly. Q. J. Med. 1993, 86: 293-299.
3. Rajasoorya C., Holdaway I.M., Wrightson P., Scott D.J., Ibbertson H.K. Determinants of clinical outcome and survival in acromegaly. Clin. Endocrinol. (Oxf.) 1994, 41: 95-102.
4. Ezzat S., Snyder P.J., Young W.F., Boyajy L.D., Newman C., Klibanski A., Molitch M.E., Boyd A.E., Sheeler L., Cook D.M., Malarkey W.B., Jackson I., Vance M.L., Thorner M.O., Barkan A., Frohman L.A., Melmed S. Octreotide treatment of acromegaly: a randomized multicenter study. Ann. Intern. Med. 1992, 177: 711-718.
5. Melmed S., Jackson I., Kleinberg D., Klibanski A. Current treatment guidelines for acromegaly. J. Clin. Endocrinol. Metab. 1998, 83: 2646-2652.
6. Roelfsema F., Frolich M., de Boer H., Harris A.G. Octreotide treatment in acromegaly: a comparison between pen-treated and pump-treated patients in a cross-over study. Acta Endocrinol. (Kbh.) 1991, 125: 43-48.
7. Heron I., Thomas F., Dero M., Poutrain J.R., Henane S., Catus F., Kuhn J.M. Treatment of acromegaly with sustained-release lanreotide, a new somatostatin analog. Presse Med. 1993, 22: 526-531.
8. Stewart P.M., Kane K.F., Stewart S.E., Lancranjan I., Sheppard M.C. Depot long-acting somatostatin analog (Sandostatin LAR) is an effective treatment for acromegaly. J. Clin. Endocrinol. Metab. 1995, 80: 3267-3272.
9. Robbins R.J. Depot somatostatin analogs - A new first line therapy for acromegaly. J. Clin. Endocrinol. Metab. 1998, 82: 15-17.
10. Caron P., Morange-Ramos I., Cogne M., Jacquet P. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J. Clin. Endocrinol. Metab. 1997, 82: 18-22.
11. Suliman M., Jenkins R., Ross R., Powell T., Battersby R., Cullen D.R. Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide. J. Endocrinol. Invest. 1999, 22: 409-418.
12. Morange I., De Boisvilliers F., Chanson P., Lucas B., Dewailly D., Catus F., Thomas F., Jacquet P. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J. Clin. Endocrinol. Metab. 1994, 79: 145-151.
13. Colao A., Marzullo P., Ferone D., Marino V., Pivonello R., Di Somma C., Di Sarno A., Giaccio A., Lombardi G. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. J. Endocrinol. Invest. 1999, 22: 40-47.
14. Marek J., Hana V., Krsek M., Justova V., Catus F., Thomas F. Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide. Eur. J. Endocrinol. 1994, 731: 20-26.
15. Giusti M., Gussoni G., Cuttica C.M., Giordano G. and the Italian Multicentre Slow Release Lanreotide Study Group. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicentre study. J. Clin. Endocrinol. Metab. 1996, 81: 2089-2097.
16. Turner H.E., Vadivale A., Keenan J., Wass J.A.H. A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clin. Endocrinol. (Oxf.) 1999, 51: 275-280.
17. Reubi J.C., Landolt A.M. The growth hormone response to octreotide in acromegaly correlates with adenoma sandostatin receptors. J. Clin. Endocrinol. Metab. 1989, 68: 844-850.
18. Giustina A., Barkan A., Casanueva F.F., Cavagnini F., Frohman L., Ho K., Veldhuis J., Wass J., Von Werder K., Melmed S. Criteria for cure of acromegaly: a consensus statement. J. Clin. Endocrinol. Metab. 2000, 85: 526-529.
19. Van der Lely A.J., Harris A.G., Lamberts S.W.J. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex. Clin. Endocrinol. (Oxf.) 1992, 37: 181-185.
20. Newman C.B., Melmed S., George A., Torigian D., Duhaney M., Snyder P., Young W., Klibanski A., Molitch M.E., Gagel R., Sheeler L., Cook D., Malarkey W., Jackson I., Vance M.L., Barkan A., Frohman L., Kleinberg D.L. Octreotide as primary treatment for acromegaly. J. Clin. Endocrinol. Metab. 1998, 83: 3034-3040.
21. Lamberts S.W.J., Uitterlinden P., Del Pozo E. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years. J. Clin. Endocrinol. Metab. 1987, 65: 703-710.
22. Bevan J.S., Webster J., Burke C.W., Scanlon M.F. Dopamine agonists and pituitary tumor shrinkage. Endocr. Rev. 1992, 13: 220-240.
23. Lancranjan J., Bruns C., Grass P., Jacquet P., Jervell J., Kendall-Taylor P., Lamberts S.W.J, Marbach P., Orskov H., Pagani G., Sheppard M., Simionescu L. Sandostatin-LAR: a promising therapeutic tool in the management of acromegalic patients. Metabolism 1996, 45: 67-71.
24. Johnson M.R., Chowdrey H.S., Thomas F., Grint C., Lightman S.L. Pharmacokinetics and efficacy of the long-acting somatostatin analogue somatuline in acromegaly. Eur. J. Endocrinol. 1994, 130: 229-234.
25. Al-Maskari M., Gebbie J., Kendall-Taylor P. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly. Clin. Endocrinol. (Oxf.) 1996, 45: 415-421.
26. Tauber J.P., Poncet M.F., Harris A.G., Barthel H.R., Simonetta-Chateauneuf C., Buscail L., Bayard F. The impact of continuous subcutaneous infusion of octreotide on gallstone formation in acromegalic patients. J. Clin. Endocrinol. Metab. 1995, 80: 3262-3266.